Search research articles
Contact Us
Filters
Showing results (821-830 of 831) with videos related to
Page
of 84
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
ESMO Open
|
October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M Tolaney, Nabihah Tayob, Chau Dang, et al.
The Lancet. Oncology
|
January 18, 2021
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L Mayer, Amylou C Dueck, Miguel Martin, et al.
NPJ Breast Cancer
|
February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Breast Cancer Research and Treatment
|
June 13, 2021
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.
Obesity (Silver Spring, Md.)
|
August 26, 2020
Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial
, Hsin-Chieh Yeh, John P Bantle, et al.
Nature Cancer
|
December 30, 2022
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
Susana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, et al.
Page
of 84
Search research articles
Search
Showing results (821-830 of 831) with videos related to
Sort By:
Page
of 84
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
ESMO Open
|
October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M Tolaney, Nabihah Tayob, Chau Dang, et al.
The Lancet. Oncology
|
January 18, 2021
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L Mayer, Amylou C Dueck, Miguel Martin, et al.
NPJ Breast Cancer
|
February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Breast Cancer Research and Treatment
|
June 13, 2021
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
Kathryn J Ruddy, Yue Zheng, Nabihah Tayob, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.
Obesity (Silver Spring, Md.)
|
August 26, 2020
Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial
, Hsin-Chieh Yeh, John P Bantle, et al.
Nature Cancer
|
December 30, 2022
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
Susana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, et al.
Page
of 84